Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance
Full-Year Guidance Raised Again With Wegovy Factored In
The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus.
